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Background: Self-monitoring and self-management, crucial for optimal glucose control in type 1 diabetes, requires many
disease-related decisions per day and imposes a substantial disease burden on people with diabetes. Innovative technologies that
integrate relevant measurements may offer solutions that support self-management, decrease disease burden, and benefit diabetes
control.
Objective: The objective of our study was to evaluate a prototype integrated mobile phone diabetes app in people with type 1
diabetes.
Methods: In this exploratory study, we developed an app that contained cloud-stored log functions for glucose, carbohydrates
(including a library), insulin, planned exercise, and mood, combined with a bolus calculator and communication functions. Adults
with diabetes tested the app for 6 weeks. We assessed the feasibility of app use, user experiences, perceived disease burden
(through questionnaires), insulin dose and basal to bolus ratio, mean glucose level, hemoglobin A1c, and number of hypoglycemic
events.
Results: A total of 19 participants completed the study, resulting in 5782 data entries. The most frequently used feature was
logging blood glucose, insulin, and carbohydrates. Mean diabetes-related emotional problems (measured with the Problem Areas
in Diabetes scale) scores decreased from 14.4 (SD 10.0) to 12.2 (SD 10.3; P=.04), and glucose control improved, with hemoglobin
A1c decreasing from 7.9% (mean 62.3, SD 8 mmol/mol) to 7.6% (mean 59.8, SD 7 mmol/mol; P=.047). The incidence of
hypoglycemic events did not change. Participants were generally positive about the app, rating it as “refreshing,” and as providing
structure by reinforcing insulin-dosing principles. The app revealed substantial knowledge gaps. Logged data enabled additional
detailed analyses.
Conclusions: An integrated mobile diabetes app has the potential to improve diabetes self-management and provide tailored
educational support, which may decrease disease burden and benefit diabetes control.
(JMIR Diabetes 2018;3(4):e17)   doi:10.2196/diabetes.9531
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Introduction
Optimizing Self-Management of Type 1 Diabetes
Type 1 diabetes is an autoimmune disease that occurs in
genetically susceptible individuals and leads to the complete
absence of insulin production by pancreatic beta cells [1]. It
often debuts in childhood or early adolescence and requires
insulin replacement therapy. To reduce the risk of long-term
complications, people with diabetes aim for optimal blood
glucose control, which requires self-monitoring of blood glucose
levels at least four times daily, injection of rapid-acting insulin
before every meal and of long-acting insulin before night (or
by continuous subcutaneous insulin infusion by insulin pump),
and adjustment of insulin dose based on food (carbohydrate)
intake, actual glucose levels, intended physical activity, and
experience (self-management) [2]. Optimal self-monitoring and
self-management requires not only extensive education but also
substantial efforts from people with diabetes. Still, and
frustratingly, episodes of high and low glucose levels are often
a fact of everyday life [3]. It has been estimated that life with
type 1 diabetes requires an astonishing number of health-related
decisions, even estimated at about 180 per day [4]. Altogether,
the self-management of type 1 diabetes presents a significant
burden [5].
Technological tools and mobile apps could support people with
diabetes in everyday diabetes self-management. These include
systems that facilitate data logging to integrate the various
relevant measurements, provide educational information, and
provide decision support software. An example of decision
support software is the Bolus Wizard or bolus calculator, which
advises people with diabetes on meal insulin dose [6]. Although
technology and innovation have the potential of making a
meaningful impact on diabetes care and could offer important
solutions, clinical effects of digital health care solutions are
often poorly investigated [7,8], particularly regarding diabetes
type 1 [9-11]. Moreover, past studies focused on a limited
number of outcomes [12].
Objectives
In close collaboration with people with diabetes, the Radboud
University Medical Center (Radboudumc; Nijmegen, the
Netherlands), Royal Philips (Eindhoven, the Netherlands), and
Salesforce (San Francisco, CA, USA) developed a prototype of
an integrated mobile diabetes app to be used on a mobile phone,
including a bolus calculation function, data logging, a forum,
and direct messaging with health care providers. We studied its
potential effect on disease burden and assessed its feasibility
and participants’ experiences with this prototype app.
Methods
Design and Setting
In this exploratory study, conducted at the Radboudumc in
Nijmegen, the Netherlands, among adults with type 1 diabetes,
we compared baseline measurements with measurements taken
during and after the intervention. We also applied qualitative
methods to assess users’ experiences, barriers and facilitators
for using the app, and perceived effects. Finally, we analyzed
objective and subjective data.
The Mobile App
The integrated mobile phone diabetes app is a prototype diabetes
mobile support software app for iOS (Apple) and Android
(Google). This app was developed for use by people with type
1 diabetes and contains the functionalities presented below.
These functionalities were chosen based on technical
possibilities, clinical expert input, and opinions expressed by
people with diabetes (n=10) who were interviewed and reviewed
layout and features on two occasions during the development
process. These persons were not included in this study.
• Logbook capabilities to capture key measurements: users
can manually enter blood glucose levels, as well as
hypoglycemic events, carbohydrate intake, injected insulin
dose, expected physical activity, stress, and mood. These
data can be displayed in the app as last-entered values and
trend graphics (history values) of blood glucose (day, week,
and month views).
• Carbohydrate intake data entry support: the “meal picker”
provides a means to define personal standard meals and to
look up carbohydrate contents of frequently used
ingredients.
• Custom settings: users (or their health care providers) can
set a target blood glucose level, alarms as reminders, and
settings for the bolus calculator (eg, ratios), as well as an
on-off switch for a warning if blood glucose value entries
exceed individual limits. In the case of the entry of blood
glucose levels above 25 mmol/L, a text message appears
and direct contact with a nurse (by telephone) is offered.
• Insulin bolus advice: based on data entered and personal
settings, such as the personal carbohydrate to insulin ratio,
the app calculates bolus advice using a modified version of
an equation by Schmidt et al [6]. We removed the insulin
on board variable for safety reasons, with no dose advice
given within 3 hours.
• Secure communication: people with diabetes can
communicate with health care providers through a secure
connection.
• Online community: people with diabetes can connect with
their peers.
• Privacy and security measures: the app was developed
respecting international privacy and security standards,
including a secured connection. All data were coded, and
all users used a fake username and credentials for the app
to make sure no data were in the system that could be traced
back to an individual or his or her medical data. Data were
stored on a cloud server based in Europe and according to
the privacy and security policy of Salesforce. Moreover,
the privacy and security procedures were reviewed and
approved by Radboudumc’s and Royal Philips’ privacy and
security officers.
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Multimedia Appendix 1 provides screenshots of the app.
Participants
As this was an initial feasibility study, we recruited a
representative sample of people with type 1 diabetes from the
outpatient clinic of the Radboudumc, aged between 18 and 65
years, with a diabetes duration of at least 2 years and stable
glycemic control (hemoglobin A1c [HbA1c] between 7% and
10% [53-86 mmol/mol]), able to count their carbohydrate intake
and vary their bolus insulin dose, having a body mass index
between 18 and 35 kg/m2, and using a suitable (iOS 9 or Android
4.1. and higher) mobile phone or tablet. Participants had to be
able to speak, read and understand Dutch.
Exclusion criteria were people with serious diabetes
complications: severe retinopathy with poor vision (visual acuity
<0.5), renal failure (glomerular filtration rate <30 mL/min/1.73
m2), foot amputation, recent (<6 months) myocardial infarction
or stroke, any serious comorbidity deemed to significantly affect
participation, a history of severe hypoglycemia (requiring
third-party assistance) over the past 3 years, pregnancy or aiming
for pregnancy, or total insulin need greater than 1 U/kg/day.
Eligible people with diabetes were identified by their treating
physician and invited to participate by letter. Subsequently, they
were contacted by phone and, if they were willing to participate
and had a suitable mobile phone, they received an extensive
information package. A total of 144 potential participants were
invited, of whom 20 participated. Reasons for not participating
were perceived burden due to participation in the study, lack of
a suitable mobile phone, or inability to attend 1 of the 3
introduction meetings. The institutional review board of the
Radboud University Medical Center approved the study, and
participants signed an informed consent form at entry into the
study (ID: 2015-2013).
Study Procedures
We asked participants to record their blood glucose levels as
usual and register hypoglycemic events in a personal diary in
the 4 weeks prior to the start of the study. They were asked to
keep a glucose (food and carbohydrate intake) and insulin dose
diary for 5 days before starting to use the app. Participants
visited 1 kickoff group meeting in which the app was installed
and personalized by the nurse based on the diaries. Participants
completed 3 validated questionnaires to assess diabetes-related
emotional stress, fear of hypoglycemia, and diabetes self-care.
After approximately 1 week of using the app, participants were
contacted once for technical or medical support. In addition,
medical support was available at all times for urgent matters,
similar to regular care. After approximately 6 weeks of use,
participants returned to the study center, where they repeated
the questionnaires, including an additional survey about the
usability of the app. Then, the app was removed from the device
and respondents were interviewed individually. Before and at
the end of the study period, we determined HbA1c.
Measurements
We compared the hypoglycemic event rate during the 4 weeks
before use of the app versus the hypoglycemic events recorded
in the app and those logged by participants. The criterion for a
hypoglycemic event was a measured blood glucose level below
4 mmol/L, with or without symptoms.
We measured diabetes-related emotional distress using the
Problem Areas in Diabetes (PAID) scale, consisting of 20 items
concerning negative emotions related to diabetes, resulting in
a score from 0 to 100. The cutoff score for serious emotional
distress is 40; average reported scores are 24.6 (SD 18.7) for
type 1 diabetes [13].
The Hypoglycemia Fear Survey (HFS) [14] (in Dutch: Angst
voor Hypoglycemie Vragenlijst) consists of 13 items, exploring
worries and fears related to hypoglycemia. The sum of the scores
is calculated, and higher scores indicate greater fear of
hypoglycemia. The range is 0 to 52, and the cutoff score is 21
[13].
The Confidence in Diabetes Self-Care (CIDS) scale (in Dutch:
Diabetes zelfzorg vragenlijst) [15] consists of 21 items and
measures diabetes-specific self-efficacy—that is, the level of
confidence that people with type 1 diabetes have to perform
diabetes-specific self-care activities. It results in a score from
0 to 100, with higher scores indicating more trust. The
questionnaire assesses trust or confidence in self-care, not
whether the activities are actually done.
Participants completed the System Usability Scale (SUS) after
the test period. The SUS provides a global view of subjective
assessments of usability [16]. This short questionnaire consists
of 10 items with 5 response options and results in a score from
0 to 100. The mean usability score for a system is 68; systems
scoring 70 or above are considered to have acceptable usability,
and those scoring above 72 are considered to have good usability
[17].
Semistructured Interviews
We held semistructured interviews at the end of the study to
evaluate participants’ experiences with the app. These interviews
focused on the advantages and disadvantages of using the app
in daily practice, and on participants’ expectations for the future.
An interview guide, based on guidelines for implementation
and a framework for the evaluation of information systems in
health care, was used [18,19]. This framework contains three
domains: human, technology, and organization. In addition, we
asked participants whether they would like to continue using
this app and to rate the app on a scale from 1 (very poor) to 10
(excellent). All interviews lasted approximately 30 minutes and
were performed face-to-face, recorded, and transcribed verbatim.
Analysis
We performed analysis and statistics using IBM SPSS Statistics
version 20 (IBM Corporation) and R version 3.2.0 (R
Foundation). We did not calculate a formal sample size, given
that we considered this to be an exploratory study; the aim was
to include 20 participants in total. Normally distributed
continuous variables were described as mean (SD). Median and
interquartile values were determined when variables were not
normally distributed. Qualitative or categorical variables (ie,
baseline parameters) were described as frequencies and
percentages. HbA1c and survey scores for the PAID, HFS, and
CIDS questionnaires before and after use of the app were
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compared by paired t tests. P values <.05 were regarded as
statistically significant. We performed subgroup analyses based
on activity: we calculated the number of median entries and
created a least active group and a most active group, determined
by the number of actions in the app.
We analyzed qualitative data using standard qualitative research
methods. Two researchers independently analyzed the transcripts
to identify barriers and facilitators that could affect use of the
app, and perceived positive and negative effects of the app.
They identified advice or suggestions for improving the next
version of the app. All results were discussed until consensus
was reached. Predefined tables were used to present results.
Barriers and facilitators are presented following the framework
of Gagnon et al [20]; positive and negative effects are presented
according to Donabedian’s framework for quality of health care
[21]. This framework distinguishes between process (eg,
improved communication), structure (eg, hospital buildings),
and outcomes (eg, death) of health care.
Results
General Results
In total, 20 people with diabetes were included, of whom 19
completed the study. We excluded 1 participant on the first day
of the test, because of an ineligible mobile phone. Table 1 shows
the participants’ characteristics. As intended, the study
population was heterogeneous with respect to age, diabetes
duration and glucose control, frequency of hypoglycemic events,
and treatment: 12 people were on basal bolus, 7 on pump
therapy, 3 used continuous glucose measurement, and 4 used a
bolus calculator.
Table 1. General characteristics of the study population (n=19).
ValuesCharacteristics




25.7 (3.4)Body mass index (kg/m2), mean (SD)
22.8 (14)Duration of diabetes mellitus (years since diagnosis), mean (SD)
Hemoglobin A1c
7.9%
62.3 (7.8)mmol/mol, mean (SD)
50 (11-100)Insulin dose, U/day (range)
Insulin regimen, n (%)
12 (63)Basal bolus
7 (37)Pump therapy
Figure 1. Use of app features by individual users. BG: blood glucose measurement; carbo: carbohydrate intake; hypo: hypoglycemic event.
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Over the study period (up to 6 weeks), a total of 5782 data
entries were recorded, ranging from 29 data entries by the least
active user to 990 data entries by the most active user (median
272). On average, participants recorded 6.8 logging entries
during working days and 8.5 during weekend days. The
proportion of active users decreased from 100% (19/19) in week
1 to 78% (15/19) after 4 weeks (Multimedia Appendix 2). The
most frequently logged data were blood glucose (n=1740),
insulin (n=1378), and carbohydrates (n=1366). Figure 1 presents
participants’ use of the various app features.
Pre- Versus Poststudy Comparison
Over the study period, mean HbA1c dropped from 7.9% (62.3,
SD 8 mmol/mol) to 7.6% (59.8, SD 7 mmol/mol; P=.047). The
incidences of hypoglycemic events were 0.31 per participant
per day at baseline and 0.27 per participant per day during the
study period (P=.21). Basal to bolus ratio did not change over
the study period.
Table 2 shows results of the questionnaires on disease burden.
Mean diabetes-related emotional problems (PAID scale scores)
decreased from 14.4 (SD 10.0) to 12.2 (SD 10.3; P=.04). Based
on the dichotomized PAID score, 4 of the 19 respondents (21%)
were at risk for emotional burnout (all scores ≥40), decreasing
to 1 of 19 after the intervention period (5%). The score on the
CIDS scale seemed to increase during the study period. The
scores on the other PAID subscales, HFS, and CIDS scale did
not change notably over the intervention period. The mean SUS
score was 75.5 (SD 16.7, range 47.5-97.5) at the end of the
study (n=19), indicating good usability. Multimedia Appendix
3 provides a comparison between more active and less active
app users.
Qualitative Results
Semistructured interviews led to several insights. All users rated
the app, resulting in a mean score of 6.7 (on a scale from 1 to
10). A total of 8 respondents reported that they would prefer to
continue to use the app if this were possible.
Frequently reported facilitators were the graphic display of
blood glucose (trend) and ease of use of the app. However, a
frequently mentioned barrier was also related to complexity of
the app or that it was not easy to use. Another frequently
mentioned barrier was that retrospective data entry was not
possible in the app (although this was actually possible). Table
3 lists all reported facilitators and barriers for using the app.
Perceived positive and negative effects are presented according
to the Donabedian framework for the quality of care. Among
the six potential positive effects was that the app made
participants more aware of their own situation and more
conscious in managing their disease. The two negative effects
that were mentioned were anxiety due to a bolus suggestion that
did not reflect their personal view and the (risk of) more
hypoglycemic events. Table 4 presents a complete overview of
perceived positive and negative effects.
Other benefits that participants described from using the diabetes
app were that it was a “wake-up call” and “refreshing,” since
they had insufficient knowledge especially regarding
carbohydrate counting. A total of 11 respondents indicated that
they wished for a system with better (wireless) connections,
such as a Bluetooth connection, between their blood glucose
meter and the app, allowing for measurements to be imported,
or even with a connection with their insulin pump. Independently
of the app, 5 respondents also noted that they would like to have
a continuous blood glucose sensor, allowing them to respond
in a timelier manner. Regarding the possibility to share data
from the app, 6 respondents mentioned that they would prefer
better sharing options, such as easy exporting of data, use of
cloud solutions, or a connection with their personal health
record. The respondents would also have appreciated a more
advanced way of presenting results in the app with graphs.
Finally, respondents stated that the bolus suggestions could be
more specific for different activities: 5 respondents mentioned
that they were missing a sports mode function in the app.
Table 2. Results of Problem Areas in Diabetes (PAID), Hypoglycemia Fear Survey (HFS), and Confidence in Diabetes Self-Care (CIDS) questionnaires
(n=19).
P valueScore, mean (SD)Instrument
AfterBefore
.1117.2 (14.8)20.0 (14.9)PAID scale
.0412.2 (10.3)14.4 (10.0)Diabetes-related emotional problems
.191.3 (2.0)2.1 (3.0)Treatment-related problems
.822.8 (3.0)2.9 (2.6)Food-related problems
.240.9 (1.4)0.6 (1.0)Social support-related problems
.8925.3 (7.0)25.4 (6.4)HFS-Worry Scalea
.1382.0 (10.9)79.6 (11.3)CIDS scaleb
an=18, as 1 respondent did not answer item 12.
bn=17, as 1 respondent did not answer item 5 and 1 respondent did not answer item 10.
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Table 3. Frequencies of barriers and facilitators for using the app.
FacilitatorBarrierApp-related factors
49Design and technical concerns
02No internet access
11Adding medication: can add only half numbers or units (eg, 0.5)
05Retrospective data entry not possible
01Lack of notifications
30Graphic display of blood glucose (trend)
318Characteristics of the innovation
Ease of use or complexity
02Meal picker complex or not intuitive
02Sliders too sensitive
210Complexity of app, easy to use (NFSa)
Relative advantage (usefulness) or lack
10No need to use additional booklet to register values
04NFS
29Validity of resources
13Content available (completeness of meal picker)
02Frequency of advice (eg, lacking between 2 meals)
Bolus suggestion
01Does not take into account blood glucose trend
03Incorrect, does not correspond to personal view
10Also bolus suggestion, even when blood glucose is (too) low 
03System reliability
01Restarting the app takes too long
01Login issues
01Crashing (of app)
aNFS: not further specified.
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Table 4. Frequencies of perceived positive and negative effects according to the Donabedian model for quality of care.
NegativePositiveOutcome
021Processes
Effects on psychological domains
012More aware or conscious of disease (self-)management
01Regularity: more frequent measurements
01More precise adjustments
04More frequent blood glucose checks
01Reduced number of corrections needed
02Patient education: better insulin advice, better than blood glucose meter
318Outcomes
01Medication: reduced insulin use
Health status
01Weight loss
05More stable values (blood glucose, carbohydrates)
05Lower blood glucose levels, reduced number of high peaks
01Improved hemoglobin A1c
03Satisfaction: feeling more confident
02Knowledge: better knowledge about own glucose levels (graphs)
10Effects on psychological domains: anxiety, due to bolus suggestion that does not correspond to own estimation
20Health status: (risk of) more hypoglycemic events
Bolus Suggestion
Logging and cloud storage allowed for subsequent analysis of
several components of self-management. Of a total of 1378
insulin entries, 842 could be compared with the bolus calculator
outputs. In 569 cases, the user accepted the bolus suggestion,
whereas they reduced the suggested insulin dose in 101 cases
and increased the insulin dose in 172 cases.
The logged dataset enabled us to compare glucose profiles after
a bolus given according to the bolus suggestion versus boluses
that were lower or higher than recommended, which were not
different in this data set. More active users appeared to have
more stable blood glucose levels, carbohydrate intake, and
medication use (Figure 2). Compared with the least active
participants, active participants tended to spend less time in
hyperglycemia and more within the normal range (Figure 3).
There were no differences in the drop in HbA1c and disease
burden between the least active and most active users.
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Figure 2. Blood glucose levels, carbohydrate intake, and insulin use per day in the study, for all participants (left) and stratified by user app activity:
most and least active participants (right).
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This exploratory study with a prototype integrated mobile
diabetes app in a heterogeneous sample of people with type 1
diabetes provided a detailed, in-depth, before-and-after analysis
in an area with very limited evidence. The app, which uses the
most relevant factors for diabetes self-management to provide
a bolus suggestion, has the potential to benefit self-management,
improve glucose control, and decrease disease burden. Logging
and cloud storage allows for subsequent analysis of several
components of self-management and potential feedback. The
study revealed several barriers related to use of the app and
identified high-priority areas for further development.
Over the short study period of 6 weeks, we noticed a significant
improvement in glucose control with reduced hypoglycemia
frequency and a significant decrease in disease burden. While
this may have been an effect of using the app, the changes in
glucose control could also be explained by a study effect.
Participating in a study, keeping a diary, and discussing bolus
settings increase the time and attention people with diabetes
devote to their treatment. Measurement of disease burden did
confirm the high burden associated with diabetes. While the
decrease in disease burden may also have been a study effect,
it has also been reported that PAID scores do not easily change
over time [22]. Even when the changes are caused by a study
effect, use of the app can apparently catalyze more attention
toward diabetes management, without increasing disease burden.
The app combines several features, many of which are found
in other diabetes devices, such as insulin pumps and glucose
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meters, or offered as stand-alone functions in mobile apps. Still,
to our knowledge, the combination of most functions that are
considered basic for self-management, including blood glucose
logging, insulin dosage, carbohydrate measurement, exercise,
graphics, and chat and direct contact with health care providers
on a mobile phone app, is unique to this app [9]. The participants
were generally positive about the app, with most (79%) still
actively using it after 4 weeks, and a large proportion stating
that they would prefer to continue using it after the study. More
specifically, the bolus calculator was evaluated as a relevant
feature, and the app made them more aware of their diabetes
self-management. These results are in line with findings of a
qualitative study among adults with type 1 diabetes, which found
that users of an app with bolus suggestion generally trusted the
suggestion [23]. The bolus suggestion function was new to most
study participants, while 2 participants already using a bolus
calculator also reported that their personal settings as added by
the nurse needed to be updated. This illustrates one of the
problems of the bolus calculator: optimal use requires, first, an
appropriate determination of the insulin to carbohydrate ratio
and a correction factor and, subsequently, frequent and repeated
fine-tuning of the settings. While the use of a bolus calculator
has been associated with a slight improvement in glucose control
[24], particularly among pump users [25], not all authors have
identified benefits [26], and patients not on a pump rarely use
a bolus calculator. In another study, our own group found
improvements in neither glucose control nor disease burden
after a structured introduction of a bolus calculator to
experienced pump users versus carbohydrate and ratio education
alone [27]. In this study, the bolus suggestion seemed to provide
an educational element in reinforcing the relationship between
insulin use and carbohydrate intake.
Our study identified several educational gaps among the
participants, particularly at the level of carbohydrate counting.
While all participants had followed a structured diabetes
education, including dietary aspects and carbohydrate counting,
which had generally been repeated over time, detailed discussion
of diaries unmasked a lack of knowledge or wrong
understanding. This is not unusual among people with
long-standing diabetes, and particularly detailed carbohydrate
counting is challenging and requires a substantial time
investment. For some, this may be more than they can or are
willing to invest in the disease management. While more intense
and repeated education may be required, use of an integrated
app preferably with detailed feedback may present an
opportunity to provide tailored education.
Other Studies
Given the dearth of available apps for diabetes management,
the lack of supporting scientific evidence is compelling.
Appropriate studies on relevant outcome parameters are scarce,
particularly in type 1 diabetes. In addition, most studies have
focused on improvements in glucose control (HbA1c). Our
primary aim was to support people with diabetes in proper
decision making, hopefully resulting in decreased disease
burden. A recent review by Hood et al of studies that reviewed
apps, both controlled and uncontrolled [10], identified that
several studies in which HbA1c was significantly reduced were
of poor quality. Brzan et al reviewed 9 of approximately 500
diabetes apps available in the Apple App Store, and identified
1 app containing a bolus calculator that had been shown to
prevent hypoglycemic events [9]. A meta-analysis [12]
summarizing controlled app studies identified 3 apps for type
1 diabetes, with 2 having no effect and 1 having a nonsignificant
effect on HbA1c. Effects on other parameters were not studied.
Logging and cloud storage of data allows for subsequent analysis
of several components of self-management and potential
feedback. In our study, we analyzed the use of the bolus
suggestion, the glucose pattern, insulin use, and carbohydrate
intake before and after a hypoglycemic event and the differences
between most frequent and least frequent users. Given the
relatively small sample size and short study duration, the
additional analyses allowed for only limited conclusions.
Nevertheless, we think this possibility has great potential in
identifying individual profiles, particularly when combined with
personalized feedback. While more authors are identifying these
potentials, this area is still in its infancy. More robust study
designs including a control group are needed to formally assess
the effects of self-monitoring apps.
Our study also identified several barriers to using the app, most
of which were related to usability issues, such as lack of direct
connectivity with devices. Another known barrier is the time
needed to add information about nutrition and insulin [9].
Although we did not calculate the specific time needed, our
qualitative analysis revealed that users found it time consuming,
which could negatively influence app use. Future development
should aim for automatic connections; this seems to be feasible
with measuring devices (see below) and is already customary
with pumps. Recent developments of Bluetooth-connected
insulin pens [28] may further complement automatic input.
Finally, optical recognition of numbers on glucose meters does
not work properly under circumstances of decreased light. It
should also be realized that in current practice the choice of a
given glucose meter heavily depends on reimbursement issues.
While input through a ruler was rapid and convenient, direct
connection would still be optimal. The emergence of continuous
glucose sensors that can directly connect to mobile apps may
help in overcoming these barriers.
Strengths and Limitations
Our study had several limitations that are related to the
exploratory design. These include the small sample size, open
uncontrolled study design, and relatively short duration of
follow-up. Obviously, mobile phone use and brand version
determine patient selection. Intentionally, we did not select
study participants based on treatment (pump or multiple daily
injections) or technical savvy. Strengths of the study are that
the app contains all of the basic features for optimal
self-management and our use of the mixed-methods approach,
which allowed for both comparison of objective measures before
and after the study and assessment of subjective user
experiences. Furthermore, the large (logged) complete data set
allowed for a wealth of valuable analyses.
Conclusion
This study suggests that an integrated mobile phone app has the
potential to benefit self-management, improve glucose control,
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and decrease disease burden. It may help to better integrate
glucose measurements, carbohydrate intake, physical activity,
and insulin dose and can identify educational gaps. Logging
and cloud storage allows for subsequent analysis of several
components of self-management and potential feedback. Finally,
the study revealed several barriers to the use of the app and
identified high-priority areas for further development. Clearly,
further work is needed to advance digital support for people
with type 1 diabetes.
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